Literature DB >> 2410098

Metabolic basis of arabinonucleoside selectivity for human leukemic T- and B-lymphoblasts.

V Verhoef, A Fridland.   

Abstract

Purine analogues are potentially useful agents for selective chemotherapy of lymphoproliferative diseases. We compared the toxic effects of various arabinonucleosides against eight human T- and B-lymphoblastoid lines. The arabinosides of cytosine (ara-C), 2-fluoroadenine (F-ara-A), adenine (ara-A) and guanine (ara-G) all inhibited the growth of T-lymphoblasts at concentrations below 2 microM. Only ara-G showed strong selectivity for T-cells, as indicated by a 15- to 250-fold greater toxicity toward T-cell lines than B-cell lines. To investigate the biochemical basis for ara-G selectivity, we compared the metabolism of the arabinonucleosides in CCRF-CEM (T-) versus PF-2S (B-) lymphoblasts. Comparison of arabinonucleoside triphosphate accumulation indicated differences favoring selective ara-GTP formation in T-cells. In contrast, ara-C, ara-A, and F-ara-A formed almost corresponding amounts of their triphosphates in both cell types. Triphosphate accumulation correlated directly with inhibition of DNA synthesis in CCRF-CEM and PF-2S cells. PF-2S cells accumulated less than 20% ara-GTP from the nucleoside than did CCRF-CEM cells. Nucleoside kinase measurements showed no significant differences in arabinonucleoside phosphorylation that could account for the preferential ara-GTP accumulation in T-cells. After removal of arabinonucleoside-containing medium, ara-GTP levels in PF-2S cells declined with a half-life of 49 min whereas, in CCRF-CEM cells, the level of analogue triphosphate remained unchanged. Furthermore, the half-life of ara-CTP, ara-ATP, and F-ara-ATP in the B-cells was 3- to 5-fold longer than that of ara-GTP. These results indicate that ara-G is more selective than other known arabinonucleosides; such selectivity warrants further assessment of the therapeutic potential of this agent against T-cell malignancies and other lymphoid disorders.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2410098

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  6 in total

Review 1.  The role of transporters in the toxicity of nucleoside and nucleotide analogs.

Authors:  Christopher A Koczor; Rebecca A Torres; William Lewis
Journal:  Expert Opin Drug Metab Toxicol       Date:  2012-04-18       Impact factor: 4.481

2.  Cellular pharmacology of 1-beta-D-arabinofuranosylcytosine in human myeloid, B-lymphoid and T-lymphoid leukemic cells.

Authors:  R L Momparler; N Onetto-Pothier; D Y Bouffard; L F Momparler
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

3.  A PET Imaging Strategy to Visualize Activated T Cells in Acute Graft-versus-Host Disease Elicited by Allogenic Hematopoietic Cell Transplant.

Authors:  John A Ronald; Byung-Su Kim; Gayatri Gowrishankar; Mohammad Namavari; Israt S Alam; Aloma D'Souza; Hidekazu Nishikii; Hui-Yen Chuang; Ohad Ilovich; Chih-Feng Lin; Robert Reeves; Adam Shuhendler; Aileen Hoehne; Carmel T Chan; Jeanette Baker; Shahriar S Yaghoubi; Henry F VanBrocklin; Randall Hawkins; Benjamin L Franc; Salma Jivan; James B Slater; Emily F Verdin; Kenneth T Gao; Jonathan Benjamin; Robert Negrin; Sanjiv Sam Gambhir
Journal:  Cancer Res       Date:  2017-06-01       Impact factor: 12.701

4.  Synthesis of 9-(beta-D-arabinofuranosyl)guanine using whole cells of Escherichia coli.

Authors:  A I Zinchenko; V N Barai; S B Bokut; E I Kvasyuk; I A Mikhailopulo
Journal:  Appl Microbiol Biotechnol       Date:  1990-03       Impact factor: 4.813

5.  Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: Cancer and Leukemia Group B study 19801.

Authors:  Daniel J DeAngelo; Daohai Yu; Jeffrey L Johnson; Steven E Coutre; Richard M Stone; Alison T Stopeck; Jon P Gockerman; Beverly S Mitchell; Frederick R Appelbaum; Richard A Larson
Journal:  Blood       Date:  2007-03-07       Impact factor: 22.113

6.  SAMHD1 is a key regulator of the lineage-specific response of acute lymphoblastic leukaemias to nelarabine.

Authors:  Tamara Rothenburger; Katie-May McLaughlin; Tobias Herold; Constanze Schneider; Thomas Oellerich; Florian Rothweiler; Andrew Feber; Tim R Fenton; Mark N Wass; Oliver T Keppler; Martin Michaelis; Jindrich Cinatl
Journal:  Commun Biol       Date:  2020-06-24
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.